Catherine Thomas, MD
Internal Medicine · Birmingham, ALNPI 1689648370
Payments from drug & device makers
Across 178 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$538
- AstraZeneca$335
- Pfizer$279
- GSK$243
- Amgen$199
- Lilly USA, LLC$183
- plus $991 from 28 others
What the payments were for
- Food & beverage$2,768100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 45 | $538 |
| AstraZeneca | 21 | $335 |
| Pfizer | 17 | $279 |
| GSK | 11 | $243 |
| Amgen(2 entities) | 13 | $199 |
| Lilly USA, LLC | 12 | $183 |
| Novo Nordisk | 8 | $146 |
| Johnson & Johnson | 7 | $102 |
| Dexcom, Inc. | 5 | $83 |
| Bayer | 4 | $78 |
| Boehringer Ingelheim | 4 | $56 |
| Novartis | 2 | $50 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| Amarin Pharma, Inc. | 3 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Astellas Pharma US Inc | 2 | $31 |
| Endogastric Solutions, Inc | 1 | $30 |
| Recordati_rare_diseases_inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Merck | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Almatica Pharma LLC | 1 | $17 |
| Pulmonx Corporation | 1 | $16 |
| Vifor Pharma, Inc. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Radius Health, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$2,768 in reported general payments places this provider in the 75th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 113 | $127,154 |
| OzempicSemaglutide | 89 | $99,511 |
| EliquisApixaban | 91 | $91,351 |
| MyrbetriqMirabegron | 73 | $51,107 |
| XareltoRivaroxaban | 46 | $41,679 |
| GemtesaVibegron | 55 | $40,956 |
| JanumetSitagliptin Phos/Metformin Hcl | 38 | $39,767 |
| JardianceEmpagliflozin | 44 | $33,614 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 31 | $30,022 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $27,763 |
| RybelsusSemaglutide | 19 | $27,445 |
| Breo ElliptaFluticasone/Vilanterol | 56 | $22,468 |
| TrulicityDulaglutide | 16 | $21,435 |
| SynjardyEmpagliflozin/Metformin Hcl | 31 | $19,932 |
| JanuviaSitagliptin Phosphate | 25 | $16,581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $183 | $148,588129 claims |
| Novo NordiskOzempic, Rybelsus | $146 | $126,955108 claims |
| PfizerEliquis | $279 | $91,35191 claims |
| MerckJanumet, Janumet Xr, Januvia | $20 | $86,37094 claims |
| Boehringer IngelheimJardiance, Synjardy, Spiriva Respimat | $56 | $61,01287 claims |
| Astellas Pharma US IncMyrbetriq | $31 | $51,10773 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $243 | $50,23186 claims |
| Johnson & JohnsonXarelto | $102 | $41,67946 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $15 | $40,95655 claims |
| AstraZenecaFarxiga, Symbicort | $335 | $16,18130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Birmingham
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- William KirbyBirmingham$2.3M
- Jordan VaughnBirmingham$1.6M
- Stefanie KrickBirmingham$527K
- Ryan WeldonBirmingham$458K
- Ashraf KhanBirmingham$215K
- Robert LewisBirmingham$201K
- David WynneBirmingham$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.